What's Happening?
The 14th Tumor Models Summit in London is set to bring together over 130 experts in tumor modeling from the pharmaceutical, biotech, and model provider sectors. The summit aims to discuss recent advancements in model selection strategies to bridge the gap between research and clinical application. This year's focus is on emerging modalities, such as AbbVie's licensing agreement with Ichnos Glenmark Innovation for a trispecific antibody and Boehringer Ingelheim's partnership with Tempus. The event underscores the importance of staying updated with innovations in tumor modeling, especially with the FDA and EMA encouraging non-animal testing methods.
Why It's Important?
The summit is crucial for advancing cancer research by fostering collaboration and knowledge exchange among industry leaders. It highlights the shift towards more ethical and efficient research methods, such as non-animal testing, which could accelerate drug development and approval processes. The event also reflects the growing emphasis on personalized medicine and the need for innovative approaches to tackle complex diseases like cancer. By uniting experts, the summit aims to enhance the translational application of research findings, potentially leading to more effective cancer treatments.
